OneSkin Introduces a New Approach to Rich Creams, Designed for Skin Longevity

Powered by the OS-01 Peptide™, OS-01 FACE RICH CREAM addresses what traditional rich creams get wrong: the underlying biological changes that compromise aging skin’s ability to retain hydration.

San Francisco, CA – WEBWIRE – Tuesday, September 22, 2026

OneSkin, the skin longevity company behind the first peptide proven to reverse skin’s biological age, today launched OS-01 FACE RICH CREAM, a first-of-its-kind formula engineered to address the biological changes that drive age-related moisture loss. Powered by OneSkin’s proprietary OS-01 Peptide™ and a Dual-Phase Hydration System, OS-01 FACE RICH CREAM works at the structural level, restoring skin’s firmness, resilience and capacity to hold onto hydration long-term.

“Rich creams have historically been designed around one idea: replacing the moisture that skin has lost,” said Carolina Reis Oliveira, PhD, CEO and co-founder of OneSkin. “But aging skin undergoes what we call the Density Shift—the natural decline in collagen, elastin, hyaluronic acid and barrier function that gets accelerated around menopause, when women can lose up to 30% of their skin’s collagen in the first five years. We saw an opportunity to rethink the category from the biology of aging skin: rather than simply adding more moisture, we designed an evidence-backed formula that supports skin’s ability to retain it.”

OS-01 FACE RICH CREAM was developed by OneSkin’s multidisciplinary team of longevity scientists, including Harvard-trained PhDs across genetics, stem cell biology, tissue engineering and immunology. The team applied its expertise in aging biology to formulate beyond hydration alone—pairing the OS-01 Peptide™, which targets cellular senescence, with a potent blend of bioactives that promote collagen production, barrier-supporting lipids, and skin-conditioning ingredients.

“Aging skin isn’t just about what we lose, it’s also about what accumulates,” said Alessandra Zonari, PhD, co-founder and Chief Scientific Officer of OneSkin. “The accumulation of senescent cells—aged cells that stop functioning properly and can contribute to inflammation—is a key driver of skin aging. We developed OS-01 FACE RICH CREAM to target these ‘zombie cells,’ support the skin barrier and ultimately help skin look and function more like younger skin.”

The Science Behind OS-01 FACE RICH CREAM

OneSkin evaluated OS-01 FACE RICH CREAM through clinical testing, human ex vivo skin models, and its proprietary Vector Intelligence Scoring System, an AI-driven platform that analyzes biological responses across markers associated with skin health and aging.

Testing demonstrated improvements across hydration, density and visible signs of aging:

77% increase in a biomarker associated with hyaluronic acid production**
28%+ increase in skin’s collagen**
93% agreed their skin retained hydration better throughout the day*
97% saw a reduced appearance of fine lines and wrinkles*
93% saw improved visible firmness*

Together, the findings reflect OneSkin’s approach to skin longevity: developing skincare around the biological processes that influence how skin functions over time—not only the visible signs of aging.

OS-01 FACE RICH CREAM is available for purchase beginning September 22nd at OneSkin.co for $170, or $144.50 with subscription.

*Based on a double-blind, third-party 6-week clinical study with 29 participants aged 43-65.

**Based on ex vivo lab studies measuring KRT10 (a protein associated with barrier strength and hydration retention), collagen, ELN (a biomarker associated with elastin production), and HAS2 (a biomarker associated with hyaluronic acid production). Lab findings may not reflect outcomes in human use and do not represent whole-body aging or medical claims.

About OneSkin:

OneSkin is a longevity biotechnology company pioneering a new approach to skincare through the science of skin aging. Founded in 2016 by four PhD scientists with expertise in stem cell biology, immunology, and tissue engineering, OneSkin translates its longevity research into clinically validated skincare designed to target the biological drivers of skin aging. The company behind the proprietary OS-01 peptide proven to reverse skin’s biological age, is backed by Unilever Ventures, Prelude Growth Partners, Selva Ventures, and other leading investors.

To learn more about OneSkin’s products, peer-reviewed research, and clinical studies, visit OneSkin.co.